Figure 12.

Human organoids in the presence or absence of CAFs in response to anticancer drugs. (A) An outline of the experimental strategy used to illustrate the drug treatment on human tumor organoids with or without CAFs. (B–G) Human organoids in response to treatment with sorafenib (4 umol), regorafenib (3 umol), or 5-FU (3.5 umol) with or without CAFs. (H) Representative image of human mono-culture and co-culture with or without treatment (magnification, 20×). (I) Human CAFs in response to anticancer drugs (sorafenib, 5 umol; regorafenib, 5 umol; 5-FU, 5 umol; n = 8). (B, D, and F) Five organoids for each well were measured randomly. (B–G and I) Data are presented as means ± SD, Mann–Whitney U tests. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001. CTR, control.